ArticleScientific reports2025
The association between antenatal indomethacin exposure and persistent pulmonary hypertension of the newborn in extremely preterm infants.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The study aimed to investigate the association between antenatal indomethacin exposure and persistent pulmonary hypertension of the newborn (PPHN) in extremely preterm infants. A retrospective cohort study was conducted involving extremely preterm infants admitted from January 2022 to May 2024. Neonates were categorized into the indomethacin group and the control group based on the antenatal indomethacin exposure. The primary outcome focused on the incidence of PPHN, while secondary outcomes encompassed the incidence of moderate to severe bronchopulmonary dysplasia (BPD), mortality, respiratory distress syndrome (RDS) ≥ stage III, hemodynamically significant patent ductus arteriosus (hsPDA), spontaneous intestinal perforation (SIP), intraventricular hemorrhage (IVH) ≥ grade III, surgical necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP) ≥ stage 3. Among the 203 included neonates, there were 68 neonates in the indomethacin group and 135 neonates in the control group. A significant association was observed between antenatal indomethacin exposure and the incidence of PPHN in extremely preterm infants (OR, 6.435; 95% CI, 1.263-32.795; P = 0.031). Among the secondary outcomes, the incidence of pneumothorax in indomethacin group was higher than that in the control group (OR,10.635; 95% CI,1.217-92.94, P = 0.029). There were no significant differences between the two groups in the incidence of other secondary outcomes (P > 0.05 for all). Antenatal indomethacin exposure was found to be associated with PPHN in extremely preterm infants. Therefore, careful consideration and comprehensive assessment were necessary when using indomethacin during pregnancy. Determining the optimal timing for its administration was crucial to minimize the risk of PPHN in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.